Progressive MS: From pathophysiology to drug discovery

Marco Salvetti, Douglas Landsman, Peter Schwarz-Lam, Giancarlo Comi, Alan J. Thompson, Robert J. Fox

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No treatments exist and success in the field will generalise to other neurological conditions where neu-rodegeneration coexists with neuroinflammation. The issue is complex, and interdisciplinary approaches - uniting scientists with different competences (neurobiology, immunogenetics, etc.) and 'mindsets' (aca-demia and industry) - will be decisive. The International Progressive MS Alliance is catalysing this process through various initiatives, the most recent of which was a meeting where scientists from academia (also outside the MS field) and from industry reviewed data and strategies to determine the next steps towards the translation of current knowledge into effective therapies. Key findings are: (i). Concerted efforts are essential to prioritise pathogenetic mechanisms according to impact on the disease and druggability. (ii). Combination therapies will probably be needed, possibly early in the disease, along with new trial designs and treatment schedules. (iii). Drug screenings are a pragmatic approach hopefully enriched by the use of neural and oligodendrocyte progenitors differentiated from induced pluripotent stem cells (iPSCs). (iv). The field of network biology will increase our ability to predict therapeutic targets. (v). Genome-wide association studies (GWAS) must try to identify variants associated with disease progression.

Original languageEnglish
Pages (from-to)1376-1384
Number of pages9
JournalMultiple Sclerosis Journal
Volume21
Issue number11
DOIs
Publication statusPublished - 2015

Fingerprint

Drug Discovery
Multiple Sclerosis
Industry
Immunogenetics
Induced Pluripotent Stem Cells
Preclinical Drug Evaluations
Aptitude
Translational Medical Research
Neurobiology
Genome-Wide Association Study
Oligodendroglia
Mental Competency
Disease Progression
Appointments and Schedules
Therapeutics
Research

Keywords

  • Academic-industry collaborations
  • Multiple sclerosis
  • Progressive multiple sclerosis
  • Research agenda
  • Therapy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Salvetti, M., Landsman, D., Schwarz-Lam, P., Comi, G., Thompson, A. J., & Fox, R. J. (2015). Progressive MS: From pathophysiology to drug discovery. Multiple Sclerosis Journal, 21(11), 1376-1384. https://doi.org/10.1177/1352458515603802

Progressive MS : From pathophysiology to drug discovery. / Salvetti, Marco; Landsman, Douglas; Schwarz-Lam, Peter; Comi, Giancarlo; Thompson, Alan J.; Fox, Robert J.

In: Multiple Sclerosis Journal, Vol. 21, No. 11, 2015, p. 1376-1384.

Research output: Contribution to journalReview article

Salvetti, M, Landsman, D, Schwarz-Lam, P, Comi, G, Thompson, AJ & Fox, RJ 2015, 'Progressive MS: From pathophysiology to drug discovery', Multiple Sclerosis Journal, vol. 21, no. 11, pp. 1376-1384. https://doi.org/10.1177/1352458515603802
Salvetti M, Landsman D, Schwarz-Lam P, Comi G, Thompson AJ, Fox RJ. Progressive MS: From pathophysiology to drug discovery. Multiple Sclerosis Journal. 2015;21(11):1376-1384. https://doi.org/10.1177/1352458515603802
Salvetti, Marco ; Landsman, Douglas ; Schwarz-Lam, Peter ; Comi, Giancarlo ; Thompson, Alan J. ; Fox, Robert J. / Progressive MS : From pathophysiology to drug discovery. In: Multiple Sclerosis Journal. 2015 ; Vol. 21, No. 11. pp. 1376-1384.
@article{7a97823782e2457e8a11c7f6478e3fe2,
title = "Progressive MS: From pathophysiology to drug discovery",
abstract = "Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No treatments exist and success in the field will generalise to other neurological conditions where neu-rodegeneration coexists with neuroinflammation. The issue is complex, and interdisciplinary approaches - uniting scientists with different competences (neurobiology, immunogenetics, etc.) and 'mindsets' (aca-demia and industry) - will be decisive. The International Progressive MS Alliance is catalysing this process through various initiatives, the most recent of which was a meeting where scientists from academia (also outside the MS field) and from industry reviewed data and strategies to determine the next steps towards the translation of current knowledge into effective therapies. Key findings are: (i). Concerted efforts are essential to prioritise pathogenetic mechanisms according to impact on the disease and druggability. (ii). Combination therapies will probably be needed, possibly early in the disease, along with new trial designs and treatment schedules. (iii). Drug screenings are a pragmatic approach hopefully enriched by the use of neural and oligodendrocyte progenitors differentiated from induced pluripotent stem cells (iPSCs). (iv). The field of network biology will increase our ability to predict therapeutic targets. (v). Genome-wide association studies (GWAS) must try to identify variants associated with disease progression.",
keywords = "Academic-industry collaborations, Multiple sclerosis, Progressive multiple sclerosis, Research agenda, Therapy",
author = "Marco Salvetti and Douglas Landsman and Peter Schwarz-Lam and Giancarlo Comi and Thompson, {Alan J.} and Fox, {Robert J.}",
year = "2015",
doi = "10.1177/1352458515603802",
language = "English",
volume = "21",
pages = "1376--1384",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "11",

}

TY - JOUR

T1 - Progressive MS

T2 - From pathophysiology to drug discovery

AU - Salvetti, Marco

AU - Landsman, Douglas

AU - Schwarz-Lam, Peter

AU - Comi, Giancarlo

AU - Thompson, Alan J.

AU - Fox, Robert J.

PY - 2015

Y1 - 2015

N2 - Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No treatments exist and success in the field will generalise to other neurological conditions where neu-rodegeneration coexists with neuroinflammation. The issue is complex, and interdisciplinary approaches - uniting scientists with different competences (neurobiology, immunogenetics, etc.) and 'mindsets' (aca-demia and industry) - will be decisive. The International Progressive MS Alliance is catalysing this process through various initiatives, the most recent of which was a meeting where scientists from academia (also outside the MS field) and from industry reviewed data and strategies to determine the next steps towards the translation of current knowledge into effective therapies. Key findings are: (i). Concerted efforts are essential to prioritise pathogenetic mechanisms according to impact on the disease and druggability. (ii). Combination therapies will probably be needed, possibly early in the disease, along with new trial designs and treatment schedules. (iii). Drug screenings are a pragmatic approach hopefully enriched by the use of neural and oligodendrocyte progenitors differentiated from induced pluripotent stem cells (iPSCs). (iv). The field of network biology will increase our ability to predict therapeutic targets. (v). Genome-wide association studies (GWAS) must try to identify variants associated with disease progression.

AB - Progressive multiple sclerosis (MS) will be a major area of research interest for years to come. No treatments exist and success in the field will generalise to other neurological conditions where neu-rodegeneration coexists with neuroinflammation. The issue is complex, and interdisciplinary approaches - uniting scientists with different competences (neurobiology, immunogenetics, etc.) and 'mindsets' (aca-demia and industry) - will be decisive. The International Progressive MS Alliance is catalysing this process through various initiatives, the most recent of which was a meeting where scientists from academia (also outside the MS field) and from industry reviewed data and strategies to determine the next steps towards the translation of current knowledge into effective therapies. Key findings are: (i). Concerted efforts are essential to prioritise pathogenetic mechanisms according to impact on the disease and druggability. (ii). Combination therapies will probably be needed, possibly early in the disease, along with new trial designs and treatment schedules. (iii). Drug screenings are a pragmatic approach hopefully enriched by the use of neural and oligodendrocyte progenitors differentiated from induced pluripotent stem cells (iPSCs). (iv). The field of network biology will increase our ability to predict therapeutic targets. (v). Genome-wide association studies (GWAS) must try to identify variants associated with disease progression.

KW - Academic-industry collaborations

KW - Multiple sclerosis

KW - Progressive multiple sclerosis

KW - Research agenda

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84985902334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985902334&partnerID=8YFLogxK

U2 - 10.1177/1352458515603802

DO - 10.1177/1352458515603802

M3 - Review article

C2 - 26362902

AN - SCOPUS:84985902334

VL - 21

SP - 1376

EP - 1384

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 11

ER -